|
1. Hijova E, Chmelarova A. Short chain fatty acids and colonic health. Bratisl Lek Listy 2007;108:354. 2. Pecorino L, Editor. Molecular biology of cancer: mechanisms, targets, and therapeutics. 3rd ed. UK: Oxford University Press; 2012. 3. Wong RS. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res 2011;30:87. [ DOI:10.1186/1756-9966-30-87] 4. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95. [ DOI:10.1093/carcin/21.3.485] 5. Korsmeyer SJ, Wei MC, Saito MT, Weiler S, Oh KJ, Schlesinger PH. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000;7:1166. [ DOI:10.1038/sj.cdd.4400783] 6. Renshaw SA, Dempsey CE, Barnes FA, Bagstaff SM, Dower SK, Bingle CD, et al. Three novel Bid proteins generated by alternative splicing of the human Bid gene. J Biol Chem 2004;279:2846-55. [ DOI:10.1074/jbc.M309769200] 7. Lee JH, Soung YH, Lee JW, Park WS, Kim SY, Cho YG, et al. Inactivating mutation of the pro‐apoptotic gene BID in gastric cancer. J Pathol 2004;202:439-45. [ DOI:10.1002/path.1532] 8. Krajewska M, Zapata JM, Meinhold-Heerlein I, Hedayat H, Monks A, Bettendorf H, et al. Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 2002;4:129-40. [ DOI:10.1038/sj.neo.7900222] 9. Vaissière T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008;659:40-8. [ DOI:10.1016/j.mrrev.2008.02.004] 10. Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. The activator protein-1 transcription factor in respiratory epithelium carcinogenesis. Mol Cancer Res 2007;5:109-20. [ DOI:10.1158/1541-7786.MCR-06-0311] 11. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA 2004;101:1241-6. [ DOI:10.1073/pnas.0307708100] 12. Szyf M. Epigenetics, DNA methylation, and chromatin modifying drugs. Annu Rev Pharmacol Toxicol 2009:25;49. [ DOI:10.1146/annurev-pharmtox-061008-103102] 13. Yagi A, Byung PY. Putative anti-cancer action of Aloe vera via butyrate fermentation. J Gastroenterol Hepatol 2017:21;6:2419-24. [ DOI:10.17554/j.issn.2224-3992.2017.06.738] 14. McNabney S, Henagan T. Short chain fatty acids in the colon and peripheral tissues: a focus on butyrate, colon cancer, obesity and insulin resistance. J Nutr 2017;9:1348. [ DOI:10.3390/nu9121348] 15. Avivi-Green C, Polak-Charcon S, Madar Z, Schwartz B. Different molecular events account for butyrate-induced apoptosis in two human colon cancer cell lines. J Nutr 2002;132:1812-8. [ DOI:10.1093/jn/132.7.1812] 16. Tailor D, Hahm ER, Kale RK, Singh SV, Singh RP. Sodium butyrate induces DRP1-mediated mitochondrial fusion and apoptosis in human colorectal cancer cells. Mitochondrion 2014;16:55-64. [ DOI:10.1016/j.mito.2013.10.004] 17. Kotunia A, Wolinski J, Laubitz D, Jurkowska M, Rome V, Guilloteau P, et al. Effect of sodium butyrate on the small intestine development in neonatal piglets feed by artificial sow. J Physiol Pharmacol 2004;55:59-68. 18. Paskova L, Trtkova KS, Fialova B, Benedikova A, Langova K, Kolar Z. Different effect of sodium butyrate on cancer and normal prostate cells. Toxicol In Vitro 2013;27:1489-95. [ DOI:10.1016/j.tiv.2013.03.002] 19. Sadat Kia F, Nazemalhosseini-Mojarad E, Forouzesh F. A quantitative investigation of the Bid gene expression in biopsies from colorectal adenomas. J Dent (Tehran) 2018;76:120-8. 20. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770. [ DOI:10.1038/35037710] 21. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342. [ DOI:10.1038/35077213] 22. Yin XM. Bid, a BH3-only multi-functional molecule, is at the cross road of life and death. Gene 2006;369:7-19. [ DOI:10.1016/j.gene.2005.10.038] 23. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009:1535-7163. [ DOI:10.1158/1535-7163.MCT-08-0860] 24. Dokmanovic M, Marks PA. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005;96:293-304. [ DOI:10.1002/jcb.20532] 25. Pajak B, Orzechowski A, Gajkowska B. Molecular basis of sodium butyrate-dependent proapoptotic activity in cancer cells. Adv Med Sci 2007;52. [ DOI:10.2478/v10042-008-0019-2] 26. Yamamura T, Matsumoto N, Matsue Y, Okudera M, Nishikawa Y, Abiko Y, et al. Sodium butyrate, a histone deacetylase inhibitor, regulates Lymphangiogenic factors in oral cancer cell line HSC-3. Anticancer Res 2014;34:1701-8. 27. Han MH, Choi YH. Effects of sodium butyrate, a histone deacetylase inhibitor, on TRAIL-mediated apoptosis in human bladder cancer cells. Life Sci 2016;26:431-8. [ DOI:10.5352/JLS.2016.26.4.431] 28. Ghiaghi M, Forouzesh F, Rahimi H. Effect of sodium butyrate on LHX1 mRNA expression as a transcription factor of HDAC8 in human colorectal cancer cell lines. Avicenna J Med Biotechnol 2019;11:23-28.
|
